Taking a Closer Look at Cancer As a Metabolic Disease : Oncology Times
An abstract is unavailable.
Related Articles
A Preview of Transformational Presentations at ASCO GI 2025
Sessions of interest at the 2025 Gastrointestinal Cancers Symposium will include data on colorectal cancer, pancreatic ductal adenocarcinoma, and more.
CO-IMPACT Registry | PSMA PET & Radiotherapy
Consortium for Implementation of PSMA-PET in Prostate Cancer therapy Trials
Share that You are Attending an NCCN Event
Share that you are attending an NCCN event on your social media and encourage your colleagues to register for the event.
Advanced non-squamous NSCLC:Tiragolumab+atezo did not improve OS
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents
The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib,…
Mushroom supplement may slow prostate cancer progression
White button mushrooms promoted antitumor activity among men with prostate cancer, according to results of an ongoing randomized phase 2 trial.Treatment with white button mushroom…
Association of Social Determinants of Health With the… : Journal of Glaucoma
ther social determinants of health are associated with undergoing treatment with laser trabeculoplasty (LTP) among individuals with ocular hypertension (OHT) or mild or moderate primary…
CA: A Cancer Journal for Clinicians: Vol 75, No 1
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
NCCN publishes patient resource on genetic testing to guide patient decisionmaking – The Cancer Letter
The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The…
Behind the Phase 3 AURIGA Trial in Newly Diagnosed Multiple Myeloma
Ashraf Z. Badros, MB, ChB, discusses the background, methods, and design of the phase 3 AURIGA trial.
